ID: ALA292067

Max Phase: Preclinical

Molecular Formula: C16H16N2O8

Molecular Weight: 364.31

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCCNC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1

Standard InChI:  InChI=1S/C16H16N2O8/c19-9-3-7(4-10(20)13(9)23)15(25)17-1-2-18-16(26)8-5-11(21)14(24)12(22)6-8/h3-6,19-24H,1-2H2,(H,17,25)(H,18,26)

Standard InChI Key:  CUKAJLUIIBQEDU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 364.31

Molecular Weight (Monoisotopic): 364.0907

AlogP: 0.08

#Rotatable Bonds: 5

Polar Surface Area: 179.58

Molecular Species: NEUTRAL

HBA: 8

HBD: 8

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 7.73

CX Basic pKa:

CX LogP: 0.10

CX LogD: -0.08

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.27

Np Likeness Score: -0.04

References

1. Brevitt SE, Tan EW..  (1997)  Synthesis and in vitro evaluation of two progressive series of bifunctional polyhydroxybenzamide catechol-O-methyltransferase inhibitors.,  40  (13): [PMID:9207944] [10.1021/jm9605187]

2.  (2015)  Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism, 

Source

Source(2):

• Scientific Literature
• BindingDB Database